Edgestream Partners’s Axsome Therapeutics AXSM Stock Holding History

Edgestream Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-56,364	Closed	-$10.3M	–	884
2025 Q4	$10.3M	Buy	56,364 +38,018	+207%	+$5.31M	0.29%	58
2025 Q3	$2.23M	Sell	18,346 -51,615	-74%	-$5.81M	0.07%	500
2025 Q2	$7.3M	Sell	69,961 -125	-0.2%	-$13.2K	0.2%	178
2025 Q1	$8.17M	Buy	+70,086	New	+$7.98M	0.28%	85

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edgestream Partners's AXSM Position: Q1 2026 in Review

Edgestream Partners sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 56,364 shares — an estimated $10.3M sold.

Edgestream Partners first reported a position in AXSM in Q1 2025 and held it in 4 quarters. The position peaked at $10.3M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Edgestream Partners reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Edgestream Partners sold 56,364 Axsome Therapeutics shares in Q1 2026, an estimated $10.3M.
Edgestream Partners first reported a position in Axsome Therapeutics in Q1 2025 and held it in 4 quarters.
Edgestream Partners's Axsome Therapeutics position peaked at $10.3M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.